<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169247</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC-TREMPLIN</org_study_id>
    <nct_id>NCT00169247</nct_id>
  </id_info>
  <brief_title>Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation</brief_title>
  <official_title>Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe d'Etude des Tumeurs de la Tête Et du Cou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      Larynx preservation remains a very challenging approach in patients with larynx/pharynx
      cancer. A first attempt consisted of induction chemotherapy followed in good responders by
      irradiation. This approach allowed to preserve 60 % of the larynx without any significant
      difference in survival. The second attempt consisted of concurrent chemo-irradiation. This
      approach provided a higher larynx preservation rate but survival remained unchanged and
      mucosal toxicity was also higher. A third approach is currently under evaluation: induction
      chemotherapy followed by concurrent chemo-irradiation in good responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At ASCO 2004 there were 3 major presentations issuing an increasing in survival:

        -  the update of the MACH-NC meta-analysis showed that actually only concurrent
           chemo-irradiation trials found a significantly improved survival (in particular the
           addition of cisplatinum alone to radiotherapy)

        -  the addition of docetaxel to the cisplatinum-5FU regimen (TPF) when compared with
           cisplatinum--5FU (PF)

        -  the addition of cetuximab to irradiation

      On this basis we decided to carry-out a randomized phase II for previously untreated patients
      requiring a total laryngectomy:

      All patients after a complete work-up including a CTscan will receive 3 cycles of TPF(T: 75
      mg/m², P: 75 mg/m² and 5FU 750 mg/m²).

      Patients with response over 50 % (endoscopy and CTscan) will be randomized to receive either
      irradiation (70 Gy) and cisplatinum (100 mg/m² on D1, D22 and D43) or irradiation (70 Gy)
      with cetuximab (loading dose of 400 mg followed by weekly 250 mg for a total of 8 cycles.

      Patients with less than 50% decease in tumour volume after TPF, patients with residual or
      recurrent disease after either RT-CDDP or RT-cetuximab will get salvage total laryngectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of laryngeal preservation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Larynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy 70 Gy, 35 fractions</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Larynx or hypopharynx squamous cell carcinoma proven by histology, locally advanced,
             only eligible for surgery as total or sub-total (pharyngo-)laryngectomy

          -  Performance status 0-1

          -  Neutrophils &gt;=1.5 x 109/l, Platelets count &gt;=100 x 109/l, haemoglobin &gt;=10 g/dl

          -  Total bilirubin &lt;= 1.5 x upper reference range

          -  ASAT and ALAT &lt;= 2.5 x upper reference range, Alkaline Phosphatases &lt;= 5 x upper
             reference range

          -  Serum creatinine &lt;= 120 µmol/l

          -  Weight loss &lt; 10 % within last 3 months

          -  Written inform consent

        Exclusion Criteria:

          -  Infiltrative transglottic tumor or clinical cartilage invasion

          -  Distant metastasis

          -  Previous chemotherapy or radiotherapy

          -  Contra-indication to chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Lefebvre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gortec.org</url>
  </link>
  <link>
    <url>http://www.gettec.org</url>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <keyword>larynx cancer</keyword>
  <keyword>hypopharynx cancer</keyword>
  <keyword>larynx preservation</keyword>
  <keyword>concomitant radiochemotherapy</keyword>
  <keyword>cisplatin</keyword>
  <keyword>cetuximab</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

